Clinical Results of Transarterial Radioembolization (TARE) with Holmium-166 Microspheres in the Multidisciplinary Oncologic Treatment of Patients with Primary and Secondary Liver Cancer

Holmium-166 microspheres are used for the transarterial radioembolization (TARE) treatment of primary and secondary liver cancers. In this study, its efficacy regarding local tumor control integration into oncological sequence first 20 patients treated in our institution were examined. A total twenty-nine 166Ho-TARE procedures performed to treat hepatocellular carcinoma (HCC, fourteen patients), metastatic colorectal cancer (mCRC, four intrahepatic cholangiocarcinoma (ICC, one patient), hemangioendothelioma (HE, patient). eight patients, was initial oncologic treatment. with HCC, median treated-liver progression-free survival (PFS), overall PFS, after 10.3, 7.3, 22.1 months; mCRC, these 2.6, 2.9, 20.6 months, respectively. Survival ICC HE 5.2 0.8 Two HCC bridged transplantation, patient mCRC downstaged curative surgery. a treatment-free interval 7.3 months achieved. line previous publications, feasible option tumors, favorable clinical outcomes majority cases. It able achieve intervals, served as bridging-to-transplant, did not prevent subsequent therapies.